Abstract
Acute lymphoblastic leukemia (ALL) serves as a paradigm of the success of modern pediatric oncology. A disease that was uniformly fatal several decades ago, ALL is now associated with relative 5-year survival rates that exceed 70%(1). With this spectacular success, we have higher expectations of qua
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American journal of pediatric hematology/oncology
Paper Title
Journal
Date
